05:30 PM EDT, 09/24/2024 (MT Newswires) -- Trinity Biotech ( TRIB ) said late Tuesday it has acquired privately held Metabolomics Diagnostics in a deal that gives the latter a roughly $1.3 million enterprise valuation.

Trinity said it funded the acquisition with "just over" 270,000 American depository shares, cash and by assuming liabilities.

Metabolomics has developed the PrePsia test to accurately predict the risk of preeclampsia in pregnant women. Trinity said it plans to manufacture the test reagents in-house, with the first revenue from preeclampsia testing expected next year.

"Given the late stage of development of PrePsia, and significant synergies with Trinity Biotech's ( TRIB ) existing capabilities and infrastructure, the additional investment for commercialization in 2025 is expected to be limited," the company said.

Trinity shares were up more than 10% in after-hours activity.

Price: 1.3800, Change: +0.13, Percent Change: +10.40